Vaxent and PREVENT kick off Strep A vaccine trials
The vaccine was developed by Dr. James Dale at the University of Tennessee Health Science Center and is being commercialized by PREVENT and Vaxent. The Phase I trial was announced in August.
In the Media Tag: streptococcus vaccine
Strep throat vaccine developed by Memphis doctor to begin clinical trial
Dr. James B. Dale developed StreptAnova at the University of Tennessee Health Sciences Center. . . StreptAnova will soon undergo a Phase 1 clinical trial in Halifax, Nova Scotia, to test its effectiveness and whether it is safe for humans.
StreptAnova® Phase 1 clinical trial to start: Vaccine designed to prevent Streptococcus pyogenes infections
StreptAnova® was invented by James B. Dale, M.D., Chief of the Division of Infectious Diseases, and Gene H. Stollerman, M.D., Endowed Professor in Medicine at the University of Tennessee Health Science Center (UTHSC), and Research Scientist at the Memphis Veterans Affairs Medical Center. It is being commercialized jointly by PREVENT and Vaxent, a company founded… Read More
Streptococcus Vaccine Clinical Trial to Begin
StreptAnova® was invented by Dr. James B. Dale at the University of Tennessee Health Science Center (UTHSC), and is being commercialized jointly by PREVENT and Vaxent, a company founded by Dr. Dale.
Streptococcus Vaccine Clinical Trial to Begin
StreptAnova® was invented by Dr. James B. Dale at the University of Tennessee Health Science Center (UTHSC), and is being commercialized jointly by PREVENT and Vaxent, a company founded by Dr. Dale.